Loading…
The Progress and Future of US Newborn Screening
Progress in newborn screening (NBS) has been driven for 60 years by developments in science and technology, growing consumer advocacy, the actions of providers involved in the care of rare disease patients, and by federal and State government funding and policies. With the current explosion of clini...
Saved in:
Published in: | International journal of neonatal screening 2022-07, Vol.8 (3), p.41 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983 |
---|---|
cites | cdi_FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983 |
container_end_page | |
container_issue | 3 |
container_start_page | 41 |
container_title | International journal of neonatal screening |
container_volume | 8 |
creator | Watson, Michael S Lloyd-Puryear, Michele A Howell, R Rodney |
description | Progress in newborn screening (NBS) has been driven for 60 years by developments in science and technology, growing consumer advocacy, the actions of providers involved in the care of rare disease patients, and by federal and State government funding and policies. With the current explosion of clinical trials of treatments for rare diseases, the pressure for expansion has grown, and concerns about the capacity for improvement and growth are being expressed. Genome and exome sequencing (GS/ES) have now opened more opportunities for early identification and disease prevention at all points in the lifespan. The greatest challenge facing NBS stems from the conditions most amenable to screening, and new treatment development is that we are screening for rare genetic diseases. In addition, understanding the spectrum of severity requires vast amounts of population and genomic data. We propose recommendations on improving the NBS system and addressing specific demands to grow its capacity by: better defining the criteria by which screening targets are established; financing the NBS system's responsiveness to opportunities for expansion, including engagement and funding from stakeholders; creating a national quality assurance, data, IT, and communications infrastructure; and improving intra-governmental communications. While our recommendations may be specific to the United States, the underlying issues should be considered when working to improve NBS programs globally. |
doi_str_mv | 10.3390/ijns8030041 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_effae7a4000a43fc8f581638bb840b54</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_effae7a4000a43fc8f581638bb840b54</doaj_id><sourcerecordid>2695288642</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983</originalsourceid><addsrcrecordid>eNpdkV1LHDEUhofSUsV61fsy0JuCbE1y8nlTKFJbQWpBhd6FJHOyzjKb2GSm4r93tmtl9SoheXh4z3mb5j0lnwEMOe5XqWoChHD6qtlnnJiFoOL36537XnNY64oQQgVXoOBtswdCG8YV3W-Or26w_VXysmCtrUtdezqNU8E2x_b6sv2Jdz6X1F6Ggpj6tHzXvIluqHj4eB4016ffrk5-LM4vvp-dfD1fBK7EuIBIGfERPAFvOAfJVaAGoItSBVDCKWI8Bsl8ZIoH4NELKglhHTIDRsNBc7b1dtmt7G3p167c2-x6--8hl6V1ZezDgBZjdKgcnyd0HGLQUWgqQXuvOfGCz64vW9ft5NfYBUxjccMz6fOf1N_YZf5rDTApGZsFnx4FJf-ZsI523deAw-AS5qlaJo1gWku-QT--QFd5KmlelWWKSiGIMhvqaEuFkmstGJ_CUGI3vdqdXmf6w27-J_Z_i_AAn4GbmQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2716550792</pqid></control><display><type>article</type><title>The Progress and Future of US Newborn Screening</title><source>PubMed (Medline)</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Coronavirus Research Database</source><creator>Watson, Michael S ; Lloyd-Puryear, Michele A ; Howell, R Rodney</creator><creatorcontrib>Watson, Michael S ; Lloyd-Puryear, Michele A ; Howell, R Rodney</creatorcontrib><description>Progress in newborn screening (NBS) has been driven for 60 years by developments in science and technology, growing consumer advocacy, the actions of providers involved in the care of rare disease patients, and by federal and State government funding and policies. With the current explosion of clinical trials of treatments for rare diseases, the pressure for expansion has grown, and concerns about the capacity for improvement and growth are being expressed. Genome and exome sequencing (GS/ES) have now opened more opportunities for early identification and disease prevention at all points in the lifespan. The greatest challenge facing NBS stems from the conditions most amenable to screening, and new treatment development is that we are screening for rare genetic diseases. In addition, understanding the spectrum of severity requires vast amounts of population and genomic data. We propose recommendations on improving the NBS system and addressing specific demands to grow its capacity by: better defining the criteria by which screening targets are established; financing the NBS system's responsiveness to opportunities for expansion, including engagement and funding from stakeholders; creating a national quality assurance, data, IT, and communications infrastructure; and improving intra-governmental communications. While our recommendations may be specific to the United States, the underlying issues should be considered when working to improve NBS programs globally.</description><identifier>ISSN: 2409-515X</identifier><identifier>EISSN: 2409-515X</identifier><identifier>DOI: 10.3390/ijns8030041</identifier><identifier>PMID: 35892471</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Automation ; clinical trials ; Genes ; Genetic disorders ; Genetic testing ; Genetics ; Genomes ; Information systems ; Medical screening ; Metabolism ; Molecular biology ; Newborn babies ; newborn screening ; Phenylketonuria ; Public health ; public health policy ; Rare diseases ; Research centers ; Review ; Sickle cell disease ; Task forces</subject><ispartof>International journal of neonatal screening, 2022-07, Vol.8 (3), p.41</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983</citedby><cites>FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983</cites><orcidid>0000-0001-7776-9123</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2716550792?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2716550792?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35892471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Watson, Michael S</creatorcontrib><creatorcontrib>Lloyd-Puryear, Michele A</creatorcontrib><creatorcontrib>Howell, R Rodney</creatorcontrib><title>The Progress and Future of US Newborn Screening</title><title>International journal of neonatal screening</title><addtitle>Int J Neonatal Screen</addtitle><description>Progress in newborn screening (NBS) has been driven for 60 years by developments in science and technology, growing consumer advocacy, the actions of providers involved in the care of rare disease patients, and by federal and State government funding and policies. With the current explosion of clinical trials of treatments for rare diseases, the pressure for expansion has grown, and concerns about the capacity for improvement and growth are being expressed. Genome and exome sequencing (GS/ES) have now opened more opportunities for early identification and disease prevention at all points in the lifespan. The greatest challenge facing NBS stems from the conditions most amenable to screening, and new treatment development is that we are screening for rare genetic diseases. In addition, understanding the spectrum of severity requires vast amounts of population and genomic data. We propose recommendations on improving the NBS system and addressing specific demands to grow its capacity by: better defining the criteria by which screening targets are established; financing the NBS system's responsiveness to opportunities for expansion, including engagement and funding from stakeholders; creating a national quality assurance, data, IT, and communications infrastructure; and improving intra-governmental communications. While our recommendations may be specific to the United States, the underlying issues should be considered when working to improve NBS programs globally.</description><subject>Automation</subject><subject>clinical trials</subject><subject>Genes</subject><subject>Genetic disorders</subject><subject>Genetic testing</subject><subject>Genetics</subject><subject>Genomes</subject><subject>Information systems</subject><subject>Medical screening</subject><subject>Metabolism</subject><subject>Molecular biology</subject><subject>Newborn babies</subject><subject>newborn screening</subject><subject>Phenylketonuria</subject><subject>Public health</subject><subject>public health policy</subject><subject>Rare diseases</subject><subject>Research centers</subject><subject>Review</subject><subject>Sickle cell disease</subject><subject>Task forces</subject><issn>2409-515X</issn><issn>2409-515X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkV1LHDEUhofSUsV61fsy0JuCbE1y8nlTKFJbQWpBhd6FJHOyzjKb2GSm4r93tmtl9SoheXh4z3mb5j0lnwEMOe5XqWoChHD6qtlnnJiFoOL36537XnNY64oQQgVXoOBtswdCG8YV3W-Or26w_VXysmCtrUtdezqNU8E2x_b6sv2Jdz6X1F6Ggpj6tHzXvIluqHj4eB4016ffrk5-LM4vvp-dfD1fBK7EuIBIGfERPAFvOAfJVaAGoItSBVDCKWI8Bsl8ZIoH4NELKglhHTIDRsNBc7b1dtmt7G3p167c2-x6--8hl6V1ZezDgBZjdKgcnyd0HGLQUWgqQXuvOfGCz64vW9ft5NfYBUxjccMz6fOf1N_YZf5rDTApGZsFnx4FJf-ZsI523deAw-AS5qlaJo1gWku-QT--QFd5KmlelWWKSiGIMhvqaEuFkmstGJ_CUGI3vdqdXmf6w27-J_Z_i_AAn4GbmQ</recordid><startdate>20220718</startdate><enddate>20220718</enddate><creator>Watson, Michael S</creator><creator>Lloyd-Puryear, Michele A</creator><creator>Howell, R Rodney</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7776-9123</orcidid></search><sort><creationdate>20220718</creationdate><title>The Progress and Future of US Newborn Screening</title><author>Watson, Michael S ; Lloyd-Puryear, Michele A ; Howell, R Rodney</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Automation</topic><topic>clinical trials</topic><topic>Genes</topic><topic>Genetic disorders</topic><topic>Genetic testing</topic><topic>Genetics</topic><topic>Genomes</topic><topic>Information systems</topic><topic>Medical screening</topic><topic>Metabolism</topic><topic>Molecular biology</topic><topic>Newborn babies</topic><topic>newborn screening</topic><topic>Phenylketonuria</topic><topic>Public health</topic><topic>public health policy</topic><topic>Rare diseases</topic><topic>Research centers</topic><topic>Review</topic><topic>Sickle cell disease</topic><topic>Task forces</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Watson, Michael S</creatorcontrib><creatorcontrib>Lloyd-Puryear, Michele A</creatorcontrib><creatorcontrib>Howell, R Rodney</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>International journal of neonatal screening</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Watson, Michael S</au><au>Lloyd-Puryear, Michele A</au><au>Howell, R Rodney</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Progress and Future of US Newborn Screening</atitle><jtitle>International journal of neonatal screening</jtitle><addtitle>Int J Neonatal Screen</addtitle><date>2022-07-18</date><risdate>2022</risdate><volume>8</volume><issue>3</issue><spage>41</spage><pages>41-</pages><issn>2409-515X</issn><eissn>2409-515X</eissn><abstract>Progress in newborn screening (NBS) has been driven for 60 years by developments in science and technology, growing consumer advocacy, the actions of providers involved in the care of rare disease patients, and by federal and State government funding and policies. With the current explosion of clinical trials of treatments for rare diseases, the pressure for expansion has grown, and concerns about the capacity for improvement and growth are being expressed. Genome and exome sequencing (GS/ES) have now opened more opportunities for early identification and disease prevention at all points in the lifespan. The greatest challenge facing NBS stems from the conditions most amenable to screening, and new treatment development is that we are screening for rare genetic diseases. In addition, understanding the spectrum of severity requires vast amounts of population and genomic data. We propose recommendations on improving the NBS system and addressing specific demands to grow its capacity by: better defining the criteria by which screening targets are established; financing the NBS system's responsiveness to opportunities for expansion, including engagement and funding from stakeholders; creating a national quality assurance, data, IT, and communications infrastructure; and improving intra-governmental communications. While our recommendations may be specific to the United States, the underlying issues should be considered when working to improve NBS programs globally.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35892471</pmid><doi>10.3390/ijns8030041</doi><orcidid>https://orcid.org/0000-0001-7776-9123</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2409-515X |
ispartof | International journal of neonatal screening, 2022-07, Vol.8 (3), p.41 |
issn | 2409-515X 2409-515X |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_effae7a4000a43fc8f581638bb840b54 |
source | PubMed (Medline); Publicly Available Content Database (Proquest) (PQ_SDU_P3); Coronavirus Research Database |
subjects | Automation clinical trials Genes Genetic disorders Genetic testing Genetics Genomes Information systems Medical screening Metabolism Molecular biology Newborn babies newborn screening Phenylketonuria Public health public health policy Rare diseases Research centers Review Sickle cell disease Task forces |
title | The Progress and Future of US Newborn Screening |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A14%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Progress%20and%20Future%20of%20US%20Newborn%20Screening&rft.jtitle=International%20journal%20of%20neonatal%20screening&rft.au=Watson,%20Michael%20S&rft.date=2022-07-18&rft.volume=8&rft.issue=3&rft.spage=41&rft.pages=41-&rft.issn=2409-515X&rft.eissn=2409-515X&rft_id=info:doi/10.3390/ijns8030041&rft_dat=%3Cproquest_doaj_%3E2695288642%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-3f120bf3b03b9443647c1933df67c375a709bec62bf274c34fb516002de293983%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2716550792&rft_id=info:pmid/35892471&rfr_iscdi=true |